Athersys, Inc. (ATHX) News
Filter ATHX News Items
ATHX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATHX News Highlights
- For ATHX, its 30 day story count is now at 5.
- Over the past 14 days, the trend for ATHX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- JD, MS and PRE are the most mentioned tickers in articles about ATHX.
Latest ATHX News From Around the Web
Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging PicksHere are the best longevity stocks to consider. |
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesCLEVELAND, October 16, 2023--Athersys, Inc. (Nasdaq: ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distr |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about! |
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosCLEVELAND, October 10, 2023--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients |
20 Foods Consumed By Longest Living People Every DayIn this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […] |
Athersys Licenses its Animal Health Assets to Ardent Animal HealthCLEVELAND & LEXINGTON, Ky., October 03, 2023--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent). Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! |
Athersys Director Jane Wasman Appointed Board ChairCLEVELAND, October 02, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023. Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys’ Audit Committee and |
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney TransplantationCLEVELAND, September 06, 2023--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney t |
Is Athersys Inc (ATHX) Significantly Overvalued?Unraveling the Valuation and Financial Health of Athersys Inc |